News headlines about Ironwood Pharmaceuticals (NASDAQ:IRWD) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.9731193424776 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of equities analysts recently issued reports on the stock. BidaskClub lowered shares of Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, February 5th. Zacks Investment Research lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Credit Suisse Group assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. Mizuho lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $20.00 to $16.00 in a research report on Wednesday, December 6th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $17.56.
Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $13.87 on Tuesday. Ironwood Pharmaceuticals has a 12-month low of $12.89 and a 12-month high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. The firm has a market cap of $2,080.00, a PE ratio of -14.45 and a beta of 1.28.
In other news, insider Mark G. Currie sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total transaction of $927,000.00. Following the completion of the transaction, the insider now owns 835,000 shares in the company, valued at approximately $12,900,750. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the transaction, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at $71,017,385.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,905 shares of company stock valued at $2,666,359. Insiders own 7.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-ironwood-pharmaceuticals-irwd-stock-price.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.